8AT Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Aclaris Therapeutics Inc

Watchlist Manager

Watchlist

Price: 4.122 EUR 1.23% Market Closed

Market Cap: €3.5B

A	Aclaris Therapeutics Inc SWB:8AT	US
A	Arobs Transilvania Software SA XBSE:AROBS	RO
	Li Auto Inc OTC:LAAOF	CN
I	Iberpapel Gestion SA MAD:IBG	ES
	Linedata Services SA PAR:LIN	FR
	Legrand SA F:LRC0	FR
S	SGL Carbon SE OTC:SGLFF	DE
	Mesa Laboratories Inc NASDAQ:MLAB	US
S	SGL Carbon SE DUS:SGL	DE

Profitability Summary

Aclaris Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

10%

Sustainable 3Y Average Gross Margin

26%

Declining Gross Margin

58% > 10%

Negative Operating Margin

-962%

Negative 3Y Average Operating Margin

-576%

Declining Operating Margin

-336% > -962%

Negative Net Margin

-833%

Negative 3Y Average Net Margin

-563%

Declining Net Margin

-338% > -833%

Negative Free Cash Flow Margin

-625%

Negative 3Y Average Free Cash Flow Margin

-344%

Declining Free Cash Flow Margin

-241% > -625%

Negative ROE

-48%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-156%

ROIC is Increasing

-163% > -98%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.